Silo Pharma, Inc.

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on developing novel therapeutics and drug delivery systems to address underserved central nervous system (CNS) conditions. The company's mission centers on tackling stress-induced psychiatric disorders, chronic pain, and neurological diseases. Headquartered in Sarasota, Florida, Silo Pharma aims to bring innovative solutions to patients with limited treatment options.

The company's pipeline includes several key programs. SPC-15 is an intranasal formulation under development for Post-Traumatic Stress Disorder (PTSD) and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant being developed for fibromyalgia and chronic pain relief. Additionally, Silo Pharma has preclinical assets, including SPC-14 for Alzheimer's disease and SPU-16 for multiple sclerosis. The company's research and development efforts encompass both conventional drugs and psychedelic formulations, often in collaboration with leading academic institutions.

Recent notable developments for Silo Pharma include its strategic expansion into the AI agent market with the acquisition of the Qwikagents platform in April 2026. The company has also seen advancements in its PTSD program, SPC-15, following a U.S. executive order aimed at accelerating psychedelic research and securing a European patent for a novel PTSD prevention therapy in April 2026. Led by Founder and CEO Eric Weisblum, Silo Pharma is positioned as a company leveraging collaborations with institutions like Columbia University and the University of Maryland, Baltimore, to advance its therapeutic candidates and pursue a streamlined regulatory pathway for faster drug approval.

Latest updates

Federal Push Accelerates Psychedelic Therapy Development, Boosting Silo Pharma

Event summary

  • The U.S. federal government is accelerating the development of psychedelic-based therapies for mental health disorders.
  • The Advanced Research Projects Agency for Health (ARPA-H) awarded grants under its EVIDENT program to institutions including Johns Hopkins University.
  • The FDA granted Investigational New Drug (IND) clearance to DemeRx for its noribogaine candidate targeting alcohol use disorder.
  • The FDA issued National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics.
  • Final guidance for psychedelic drug development from the FDA is expected imminently.

The big picture

The coordinated federal actions represent a significant validation of the psychedelic therapy sector, potentially opening up a large market for novel treatments of PTSD and related disorders. This shift is driven by a recognized need for new approaches to mental health, particularly among veterans, and is likely to spur increased investment and competition within the biopharmaceutical industry. Silo Pharma's diversified portfolio positions it to benefit, but also exposes it to the risks inherent in developmental-stage biopharma.

What we're watching

Regulatory Headwinds
The FDA’s final guidance on psychedelic drug development will be critical; its content and enforcement will significantly shape the competitive landscape and timelines for Silo Pharma and its peers.
Execution Risk
Silo Pharma’s ability to capitalize on this favorable regulatory environment and secure further funding will determine its progress on programs like SPC-15 for PTSD.
Governance Dynamics
Continued federal support for psychedelic therapies, as demonstrated by ARPA-H’s EVIDENT program, may signal a broader shift in healthcare policy and funding priorities.
CID: 2397